Efficacy and Safety of Teicoplanin in CDAD
Prospective, Interventional, Phase IV Study, Evaluating the Efficacy and Safety of Teicoplanin (100-200 mg, Administered Orally Twice a Day) in Patients With Clostridium Difficile Infection-associated Diarrhea and Colitis
Sponsor: Sanofi
Terminated
Due to COVID-19 and great challenges during patient enrolment period, current status of this study is far behind the plan. The study cannot be completed according to the plan. Sanofi decides to terminate the study upon comprehensive assessment.
This PHASE4 trial investigates Clostridium Difficile Infection-associated Diarrhea and Colitis and is currently terminated or withdrawn. Sanofi leads this study, which shows 13 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
13 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Oct 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE4
-
Dec 2021 — May 2022 [monthly]
Terminated PHASE4
▶ Show 8 earlier versions
-
Jun 2021 — Dec 2021 [monthly]
Terminated PHASE4
Status: Completed → Terminated
-
May 2021 — Jun 2021 [monthly]
Completed PHASE4
Status: Recruiting → Completed
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE4
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE4
-
Jun 2020 — Sep 2020 [monthly]
Recruiting PHASE4
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE4
-
Sep 2019 — May 2020 [monthly]
Not Yet Recruiting PHASE4
-
Aug 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .